Market revenue in 2023 | USD 1,389.0 million |
Market revenue in 2030 | USD 2,254.6 million |
Growth rate | 7.2% (CAGR from 2023 to 2030) |
Largest segment | Glucose testing |
Fastest growing segment | Glucose testing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Glucose testing, A1C testing, Direct LDL testing, Lipid panel testing, Prostate-specific antigen testing, COVID-19 testing, BUN testing, Vitamin D testing, Thyroid-stimulating hormone testing, Serum Nicotine / Cotinine testing, High sensitivity CRP testing, Testosterone testing, ALT testing, Cortisol testing, Creatinine testing, AST testing, Other blood tests |
Key market players worldwide | Abbott Laboratories, Roche Holding AG ADR, Bio-Rad Laboratories Inc, BioMerieux SA, Quest Diagnostics Inc, Biomerica Inc, Becton Dickinson & Co, Siemens Healthineers AG ADR, Danaher Corp, Trinity Biotech PLC ADR |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to blood testing market will help companies and investors design strategic landscapes.
Glucose testing was the largest segment with a revenue share of 15.07% in 2023. Horizon Databook has segmented the Russia blood testing market based on glucose testing, a1c testing, direct ldl testing, lipid panel testing, prostate-specific antigen testing, covid-19 testing, bun testing, vitamin d testing, thyroid-stimulating hormone testing, serum nicotine / cotinine testing, high sensitivity crp testing, testosterone testing, alt testing, cortisol testing, creatinine testing, ast testing, other blood tests covering the revenue growth of each sub-segment from 2018 to 2030.
Rising prevalence of chronic diseases such as diabetes, cardiovascular diseases, and other target diseases is anticipated to drive the market growth in Russia. According to a report published by the International Diabetes Federation, about 8,288,500 individuals were diagnosed with diabetes in 2019 in the country.
The prevalence of the disease in adults was 7.8% of the total population. Russia also accounts for the highest mortality rate due to cardiovascular diseases. Thus, rising incidence of chronic diseases is anticipated to fuel the market growth in the nation.
Horizon Databook provides a detailed overview of country-level data and insights on the Russia blood testing market , including forecasts for subscribers. This country databook contains high-level insights into Russia blood testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account